Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Genzyme |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Genzyme, a Sanofi Company | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the study is to find out the effects of two different drugs used at the beginning of organ transplantation on different populations of immune cells in the body of patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | patients receiving IL-2 receptor antagonist (Simulect) as induction treatment | ||
| 2 | patients receiving Thymoglobulin as induction treatment |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The primary outcome is to look for expansion of regulatory T cells at one year. | 12 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
renal transplant recipients and living donors if available
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nader Najafian, MD | Brigham and Women's Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | United States |
Not provided
Not provided
Not provided
Not provided